Altamira Therapeutics Ltd. (NASDAQ:CYTO) Sees Large Growth in Short Interest

Altamira Therapeutics Ltd. (NASDAQ:CYTO) was the target of a significant growth in short interest during the month of November. As of November 15th, there was short interest totalling 105,400 shares, a growth of 238.9% from the October 31st total of 31,100 shares. Based on an average trading volume of 74,600 shares, the short-interest ratio is presently 1.4 days. Currently, 2.8% of the company’s shares are short sold.

Altamira Therapeutics Price Performance

Shares of Altamira Therapeutics stock traded up $0.00 during trading on Wednesday, hitting $0.43. The stock had a trading volume of 11,793 shares, compared to its average volume of 724,487. Altamira Therapeutics has a 12 month low of $0.40 and a 12 month high of $17.20. The firm’s fifty day simple moving average is $0.57 and its 200-day simple moving average is $0.97.

Altamira Therapeutics Company Profile

Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens.